This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

AMRI Hires Vijay Kumar Batra As Managing Director, AMRI India

ALBANY, N.Y., Jan. 10, 2014 /PRNewswire/ -- Albany Molecular Research Inc. (NASDAQ: AMRI) today announced the appointment of Vijay Kumar Batra, to the position of Managing Director, AMRI India, effective January 2, 2014. Mr. Batra will report to Steve Hagen, Ph.D., Senior Vice President of Manufacturing and Pharmaceuticals.

"Mr. Batra brings a wealth of experience in the Active Pharmaceutical Ingredients (APIs) and intermediates business and he also brings a leadership acumen that helps AMRI continue our plan for growth in the Indian and world markets," said Dr. Hagen. "We are excited to have Vijay on our leadership team. He has a strong record of leading business growth in the area of API and intermediates and is highly respected by those who have worked with him and the businesses he has led."

Before coming to AMRI, Mr. Batra held a number of executive roles with Teva Pharmaceuticals Industries Ltd. since 2003. Most recently, he was Vice Chairman and Managing Director, Teva API India, responsible for research and development and manufacturing of API's and advanced intermediates for the global market. The facilities overseen by Mr. Batra had strong compliance records and achieved U.S. Food and Drug Administration and other international certifications. Mr. Batra also served as Chairman of Teva API China during his most recent tenure. Prior to these roles, Mr. Batra was President and Director of JK Drugs and Pharmaceuticals and Advisor at JK Pharmachem Ltd. He also held other roles with Ranbaxy, Kinetics Technology India Ltd., and Synthetics and Chemicals Ltd. Mr. Batra was also responsible for Drug Product Manufacturing and was Vice Chairman of Tevapharm India Pvt. Ltd. during his last few years.

Mr. Batra earned a Bachelor's degree in Technology from the Indian Institute of Technology and is an alumnus of the Wharton Business School's Senior Executive Development program.

About AMRIAlbany Molecular Research, Inc. (AMRI) is a global contract research and manufacturing organization offering customers fully integrated drug discovery, development and manufacturing services. For over 22 years, AMRI has demonstrated its adaptability as the pharmaceutical and biotechnology industries have undergone tremendous change in response to multiple challenges. This experience, a track record of success and locations in the United States, Europe and Asia now provides our customers with SMARTSOURCING™, a full range of value-added opportunities providing customers with informed decision-making, enhanced efficiency and more successful outcomes at all stages of the pipeline. AMRI has also successfully partnered R&D programs and is actively seeking to out-license its remaining programs for further development. For more information about AMRI, please visit our website at www.amriglobal.com or follow us on Twitter (@amriglobal).

SOURCE AMRI

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,689.86 -56.12 -0.32%
S&P 500 2,103.84 -4.79 -0.23%
NASDAQ 5,128.2810 -0.5040 -0.01%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs